Adjuvant chemotherapy

Results from an exploratory analysis of the ADAURA phase III trial have shown Osimertinib ( Tagrisso ) has extended disease-free...


Tagrisso ( Osimertinib ), an irreversible epidermal growth factor receptor tyrosine kinase inhibitor ( EGFR TKI ), has been approved...


The U.S. Food and Drug Administration ( FDA ) has approved the combination of Keytruda ( Pembrolizumab ), an anti-PD-1...


The U.S. Food and Drug Administration ( FDA ) ha approved Opdivo ( Nivolumab ) 240 mg every two weeks...



Non-small-cell lung cancer ( NSCLC ) is terminal in most patients with locally advanced stage disease. Researchers have assessed the antitumour...


The FDA ( U.S. Food and Drug Administration ) has approved Tagrisso ( Osimertinib ) as the first adjuvant treatment...


The Food and Drug Administration ( FDA ) has approved a new fixed-dose combination of Pertuzumab, Trastuzumab, and Hyaluronidase–zzxf ( Phesgo...


Erdafitinib ( Balversa ) is a pan-FGFR kinase inhibitor for treatment of adults with metastatic urothelial carcinoma ( mUC )...


Osimertinib ( Tagrisso ) is a 3rd-generation, CNS-active, epidermal growth factor receptor ( EGFR ) tyrosine kinase inhibitor ( TKI...


Pembrolizumab ( Keytruda ) monotherapy has shown promising antitumor activity and manageable safety in patients with metastatic triple-negative breast cancer...


Abemaciclib ( Verzenio ) in combination with standard adjuvant endocrine therapy has met the primary endpoint of invasive disease-free...


The phase 3 KEYNOTE-522 trial investigating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in combination with chemotherapy has met one...


The European Commission ( EC ) has approved Keytruda , an anti-PD-1 therapy, as monotherapy or in combination with Platinum...


The European Commission has approved Talzenna ( Talazoparib ), an oral poly (ADP-ribose) polymerase ( PARP ) inhibitor, as monotherapy...


Neoadjuvant, or pre-surgical, treatment with Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ) resulted in an overall major pathologic...


Role of aromatase inhibitors and Zoledronic acid ( Zometa ) as adjuvant treatment of premenopausal endocrine-responsive breast cancer patients is...


Although immune checkpoint inhibitors ( ICI ) have improved outcomes in some patients with Platinum-resistant metastatic urothelial carcinoma ( mUC...


The FDA ( Food and Drug Administration ) has approved Opdivo ( Nivolumab ) injection, for intravenous use for the...


The US Food and Drug Administration ( FDA ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the...